On Friday, Cara Therapeutics Inc (NASDAQ: CARA) was -5.04% drop from the session before settling in for the closing price of $0.33. A 52-week range for CARA has been $0.24 – $1.31.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 115.17% over the last five years. With a float of $45.77 million, this company’s outstanding shares have now reached $54.48 million.
The firm has a total of 55 workers. Let’s measure their productivity. In terms of profitability, gross margin is 84.43%, operating margin of -944.9%, and the pretax margin is -1099.76%.
Cara Therapeutics Inc (CARA) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Cara Therapeutics Inc stocks. The insider ownership of Cara Therapeutics Inc is 16.56%, while institutional ownership is 24.76%. The most recent insider transaction that took place on Nov 04 ’24, was worth 1,064. In this transaction PRESIDENT AND CEO of this company sold 3,668 shares at a rate of $0.29, taking the stock ownership to the 168,768 shares. Before that another transaction happened on Aug 01 ’24, when Company’s PRESIDENT AND CEO sold 4,149 for $0.35, making the entire transaction worth $1,452. This insider now owns 172,436 shares in total.
Cara Therapeutics Inc (CARA) Recent Fiscal highlights
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -0.59 earnings per share (EPS) during the time that was less than consensus figure (set at -0.38) by -0.21. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.2 per share during the current fiscal year.
Cara Therapeutics Inc (NASDAQ: CARA) Trading Performance Indicators
You can see what Cara Therapeutics Inc (CARA) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 4.71. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.87.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.75, a number that is poised to hit -0.38 in the next quarter
Technical Analysis of Cara Therapeutics Inc (CARA)
Analysing the last 5-days average volume posted by the [Cara Therapeutics Inc, CARA], we can find that recorded value of 0.69 million was better than the volume posted last year of 0.65 million. As of the previous 9 days, the stock’s Stochastic %D was 45.64%. Additionally, its Average True Range was 0.03.
During the past 100 days, Cara Therapeutics Inc’s (CARA) raw stochastic average was set at 40.06%, which indicates a significant decrease from 47.10% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 76.94% in the past 14 days, which was lower than the 78.92% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.2863, while its 200-day Moving Average is $0.5155. Now, the first resistance to watch is $0.3291. This is followed by the second major resistance level at $0.3470. The third major resistance level sits at $0.3641. If the price goes on to break the first support level at $0.2941, it is likely to go to the next support level at $0.2770. Now, if the price goes above the second support level, the third support stands at $0.2591.
Cara Therapeutics Inc (NASDAQ: CARA) Key Stats
There are 54,847K outstanding shares of the company, which has a market capitalization of 16.21 million. As of now, sales total 20,970 K while income totals -118,510 K. Its latest quarter income was 990 K while its last quarter net income were -20,020 K.
